Evaluation of Annual Reports of Banks in Comparative Perspective
New Challenges in Accounting and Finance · 2020
DOI: 10.32038/ncaf.2020.04.02 ↗Kurz gefasst
Fachartikel in der Zeitschrift New Challenges in Accounting and Finance, 2020. Verfasst von Tunga BOZDOĞAN und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Banks are one of the most important units of the economic structure today. From the top public authority to the smallest investor, administrators who are responsible for the economy need information about the bank's financial situation and operational results. This information, required by decision-makers, is given by the annual reports prepared by the bank. The annual reports should be presented in a clear, understandable and comparable way to meet the required information of the relevant decision-makers. The purpose of this study is to analyze the content of bank annual reports from a comparative perspective. In this framework, Introduction, Corporate Governance, Financial Reporting and Activities Analysis and Evaluation of the Annual Reports of JP Morgan Chase Bank, which is the United States' largest bank, and Is bank of Turkey, which is Turkey's largest private sector bank, were compared by total assets by the end of 2019 with this study. The differences between the banks were tried to be determined and the determined differences were evaluated according to their level of importance.
Zitieren
APA
BOZDOĞAN, T., & ERDOĞAN, H. (2020). Evaluation of Annual Reports of Banks in Comparative Perspective. New Challenges in Accounting and Finance. https://doi.org/10.32038/ncaf.2020.04.02
Vancouver
BOZDOĞAN T, ERDOĞAN H. Evaluation of Annual Reports of Banks in Comparative Perspective. New Challenges in Accounting and Finance. 2020. doi:10.32038/ncaf.2020.04.02
BibTeX
@article{BOZDOAN2020,
author = {BOZDOĞAN, Tunga and ERDOĞAN, Halil},
title = {Evaluation of Annual Reports of Banks in Comparative Perspective},
journal = {New Challenges in Accounting and Finance},
year = {2020},
doi = {10.32038/ncaf.2020.04.02}
}
EUVIMED